SCHEMBL7126319

SCHEMBL7126319

COc1cccc(S(=O)(=O)C2CS(O)(O)c3ccccc32)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.40
KEAP1 Q14145 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PGR P06401 2/20 0.39
HSD11B1 P28845 1/20 0.39
MEP1B Q16820 1/20 0.38
CTSG P08311 1/20 0.38
CMA1 P23946 1/20 0.38
HTR6 P50406 2/20 0.38
FFAR4 Q5NUL3 1/20 0.38
AURKA O14965 1/20 0.38
KDR P35968 1/20 0.38
AURKB Q96GD4 1/20 0.38
KAT6A Q92794 2/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7131527 0.87 MMP13 (0.43) NFE2L2KEAP1L3MBTL1LMNATSHR
SCHEMBL7127164 0.86 HSD11B1 (0.42) L3MBTL1PGRHSD11B1HTR6KAT6A
SCHEMBL7126323 0.86 NFE2L2 (0.41) NFE2L2KEAP1L3MBTL1PGRCTSG
SCHEMBL7157334 0.84 PPARD (0.34) KAT6A
SCHEMBL7126781 0.84 CA2 (0.43) HTR6LMNAALDH1A1
SCHEMBL7689832 0.84 ITGB3 (0.40) HTR6
SCHEMBL7132896 0.84 CHRNB2 (0.43) LMNAALDH1A1
SCHEMBL7134183 0.84 L3MBTL1 (0.40) L3MBTL1PGRHSD11B1HTR6KAT6A
SCHEMBL7133412 0.83 CA2 (0.35) HTR6KAT6A
Hydrochloric Acid SCHEMBL7160422 0.83 ITGB3 (0.39) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO NFE2L2 609/4885KEAP1 1614/4885L3MBTL1 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.